Cargando…

Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND AND OBJECTIVE: Relevant data of PARADIGM-HF reveals sacubitril/valsartan (SV) therapy led to a greater reduction in the risks of arrhythmia, and sudden cardiac death than angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor inhibitor (ARB) therapy in HFrEF, however, inconsi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ruxin, Ye, Haowen, Ma, Li, Wei, Jinjing, Wang, Ying, Zhang, Xiaofang, Wang, Lihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289747/ https://www.ncbi.nlm.nih.gov/pubmed/35859597 http://dx.doi.org/10.3389/fcvm.2022.890481

Ejemplares similares

Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials
por: Wang, Ruxin, et al.
Publicado: (2022)

HADH may be the target molecule of early vascular endothelial impairment in T2DM
por: Ye, Haowen, et al.
Publicado: (2022)

Effects of different types of radiation therapy on cardiac-specific death in patients with thyroid malignancy
por: Wang, Ruxin, et al.
Publicado: (2022)

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials
por: Liu, Xue-Hui, et al.
Publicado: (2022)

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach
por: Zhou, Yu, et al.
Publicado: (2022)

Effect of radiotherapy on cardiac-specific death in patients with non-malignant tumors of central nervous system and related clinical features
por: Wang, Ruxin, et al.
Publicado: (2022)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
por: Yang, Pei, et al.
Publicado: (2022)

Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
por: Guo, Yanhong, et al.
Publicado: (2022)

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials
por: Song, Yinyin, et al.
Publicado: (2022)

Clinical observation of sacubitril valsartan sodium in the treatment of resistant hypertension: A randomized clinical trial
por: Lyu, Tian-Jiao, et al.
Publicado: (2022)

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Yu, Wanqian, et al.
Publicado: (2022)

Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol
por: Lee, Vivian, et al.
Publicado: (2023)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
por: Jiang, Juan, et al.
Publicado: (2023)

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
por: Yang, Pei, et al.
Publicado: (2023)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
por: Chen, Qingsong, et al.
Publicado: (2022)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
por: Litwin, Sheldon E., et al.
Publicado: (2022)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Pascual-Figal, Domingo, et al.
Publicado: (2021)

A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction
por: Zhou, Xiaomin, et al.
Publicado: (2022)

Clinical efficacy of sacubitril-valsartan combined with acute ST-segment elevation myocardial infarction after reperfusion: A systematic review and meta-analysis
por: Zhang, Dong, et al.
Publicado: (2022)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
por: Hsu, Chien-Yi, et al.
Publicado: (2022)

Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea
por: Pelaia, Corrado, et al.
Publicado: (2022)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
por: Burgdorf, Christof, et al.
Publicado: (2021)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022)

Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis
por: Monosilio, Sara, et al.
Publicado: (2022)

Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later
por: Tao, Wenqi, et al.
Publicado: (2023)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
por: Pathadka, Swathi, et al.
Publicado: (2021)

Transfer RNA-derived small RNAs and their potential roles in the therapeutic heterogeneity of sacubitril/valsartan in heart failure patients after acute myocardial infarction
por: Su, Jia, et al.
Publicado: (2022)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
por: Medeiros, Paulo, et al.
Publicado: (2023)

Sacubitril/Valsartan: Potential Impact of ARNi “Beyond the Wall” of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19
por: Rubattu, Speranza, et al.
Publicado: (2020)

Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?
por: Mapelli, Massimo, et al.
Publicado: (2022)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
por: Sacharczuk, Wioletta, et al.
Publicado: (2023)

Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis
por: Liu, Lang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h0fnrqmf56nci7dscmaotmkh74